338
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma

, , , , , & show all
Pages 241-245 | Received 27 Apr 2011, Accepted 03 Aug 2011, Published online: 20 Dec 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Asuman Deveci Ozkan, Mehmet Sarihan & Suleyman Kaleli. (2021) Evaluation of the Effects of Nobiletin on Toll-Like Receptor 3 Signaling Pathways in Prostate Cancer In Vitro. Nutrition and Cancer 73:7, pages 1138-1144.
Read now

Articles from other publishers (12)

Xueqiong Meng, Xiaoxi Cui, Xiaoya Shao, Yanqi Liu, Yihao Xing, Victoria Smith, Shiqiu Xiong, Salvador Macip & Yixiang Chen. (2022) poly(I:C) synergizes with proteasome inhibitors to induce apoptosis in cervical cancer cells. Translational Oncology 18, pages 101362.
Crossref
Xin Zheng, Song Li & Hui Yang. (2021) Roles of Toll-Like Receptor 3 in Human Tumors. Frontiers in Immunology 12.
Crossref
Seyed Ali Mosaddad, Kimia Beigi, Tayebeh Doroodizadeh, Maral Haghnegahdar, Farzaneh Golfeshan, Reza Ranjbar & Hamid Tebyanian. (2021) Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update. European Journal of Pharmacology 890, pages 173657.
Crossref
Yash Sharma & Kumud Bala. (2020) Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma. Oncology Reviews 14:1.
Crossref
Jiaojiao Zhao, Yaxian Xue, Yuchen Pan, Anran Yao, Guoqun Wang, Dan Li, Tingting Wang, Shuli Zhao & Yayi Hou. (2018) Toll‐like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3‐UNC93B1‐IFN‐β signaling axis in paclitaxel‐resistant colon cancer. Journal of Cellular Physiology 234:5, pages 7051-7061.
Crossref
Lugain Alkurdi, François Virard, Béatrice Vanbervliet, Kathrin Weber, Florent Toscano, Marc Bonnin, Nolwenn Le Stang, Sylvie Lantuejoul, Olivier Micheau, Toufic Renno, Serge Lebecque & Yann Estornes. (2018) Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. Cell Death & Disease 9:9.
Crossref
Yann Estornes, Toufic Renno & Serge Lebecque. 2017. TRAIL, Fas Ligand, TNF and TLR3 in Cancer. TRAIL, Fas Ligand, TNF and TLR3 in Cancer 159 185 .
Kevin D. McCormick, Arundhati Ghosh, Sumita Trivedi, Lin Wang, Carolyn B. Coyne, Robert L. Ferris & Saumendra N. Sarkar. (2016) Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis 37:5, pages 522-529.
Crossref
Yo Han ChoiChang Hoon BaeHyeong Geun KimBo Hyeon SeoYoon Seok ChoiSi-Youn SongYong-Dae Kim. (2015) Effect of Polyinosinic-Polycytidylic Acid on MUC5B Expression in Human Airway Epithelial Cells. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 58:9, pages 615.
Crossref
K Zeljic, G Supic, N Jovic, R Kozomara, M Brankovic‐Magic, M Obrenovic & Z Magic. (2013) Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Diseases 20:4, pages 416-424.
Crossref
Wen-Ming Hsu, Chao-Cheng Huang, Pei-Yi Wu, Hsinyu Lee, Min-Chuan Huang, Ming-Hong Tai & Jiin-Haur Chuang. (2013) Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Letters 336:2, pages 338-346.
Crossref
Saskia Stier, Claudia Maletzki, Ulrike Klier & Michael Linnebacher. (2013) Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. Clinical and Developmental Immunology 2013, pages 1-14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.